What is Attovia Therapeutics, Inc. (ATTO)?

Attovia Therapeutics, Inc. (ATTO) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ATTO?

The current price of ATTO is $15.00. Prices are updated in real time on Stocks360.

What is ATTO's price-to-earnings (PE) ratio?

ATTO's trailing twelve-month PE ratio is -16.13, based on current price and earnings per share data available on Stocks360.

What is ATTO's market capitalization?

ATTO's market capitalization is $684,768,900.00, placing it in the small-cap tier.

Attovia Therapeutics, Inc. (ATTO)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$15.00

Market Cap

$684.77M

PE (TTM)

-16.13

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.00

Day Range

$13.63 – $15.05

52-wk Range

$12.94 – $28.00

Avg Volume

N/A

Volume

454.27K

Attovia Therapeutics, Inc. (ATTO) is a publicly traded company in the Healthcare sector. Latest price: $15.00. Market cap $684.77M. Trailing PE -16.13. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2026-08-05 · $21.90 2026-10-27 · $15.00 (-31.51%)

Earnings

Most Recent

Sep 2, 2026

EPS $-4.88 vs est. $-0.65

Missed by $4.23

Next Earnings

Dec 2, 2026

EPS estimate $-0.56

Proprietary Signals

Signal snapshot temporarily unavailable.

About Attovia Therapeutics, Inc.

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-16.13×
P/S (TTM)	1521.71×
P/B	6.07×
PEG	0.19×
P/FCF (TTM)	-19.40×
EV / EBITDA	-15.90×
EV / Sales	1458.37×
Earnings Yield	-5.75%
Free Cash Flow Yield	-5.15%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$656.27M
Revenue (TTM)	$450.00K
Net Income (TTM)	-$39.34M
Free Cash Flow (TTM)	-$35.29M
Net Debt	-$28.50M
Working Capital	$105.79M
Gross Margin	-8.44%
Operating Margin	-9279.56%
Net Margin	-8742.89%
Return on Equity	-32.05%
Return on Invested Capital	-35.46%